A new CRISPR-powered light sensor can detect the faintest molecular signs of cancer in a drop of blood. A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNAnanotechnology, CRISPR, and quantumdots to generate a clear signal from just a few molecules. In lung cancer tests, it worked even in real patient serum samples. Researchers hope it could eventually power portable blood tests for cancer and other diseases.
Scientists have designed a powerful light based sensor capable of detecting extremely small amounts of cancer biomarkers in blood. The innovation could eventually allow doctors to identify early warning signs of cancer and other diseases through a routine blood draw.
Biomarkers such as proteins, fragments of DNA, and other molecules can signal whether cancer is present, how it is progressing, or a person’s risk of developing it. The difficulty is that in the earliest stages of disease, these markers exist in extremely low concentrations, making them hard to measure with conventional tools.









